Tags

Type your tag names separated by a space and hit enter

Topical 8-methoxypsoralen enhances the therapeutic results of targeted narrowband ultraviolet B phototherapy for plaque-type psoriasis.
J Eur Acad Dermatol Venereol. 2008 Jan; 22(1):50-5.JE

Abstract

Targeted broadband ultraviolet B (UVB) phototherapy as well as 308-nm excimer laser have been reported to significantly improve or clear localized psoriatic plaques within 5 to 10 treatments when medium fluences [i.e. 4-6 multiples of minimal erythema doses (MED)] were used. Our study was conducted to determine the effects of different concentrations of topical 8-methoxypsoralen (8-MOP) cream when used in combination with targeted UV phototherapy with regard to number of treatments and cumulative UV doses to clear localized psoriasis. Ten evaluable patients with stable plaque-type psoriasis completed the study. Three different concentrations of 8-MOP creams (0.001%, 0.01% and 0.1%) were applied prior to irradiation with 4 MEDs of targeted narrowband UVB (NB-UVB), whereas 0.001% 8-MOP cream was used in conjunction with 5 J/cm(2) UVA. All irradiations took place once weekly for 12 weeks. Psoriasis severity index (PSI) score was used to evaluate the efficacy of the treatment. With area-under-the-curve analysis, 0.1% 8-MOP/NB-UVB was superior to other modalities in reducing the PSI scores. The number of treatments and cumulative NB-UVB doses necessary to achieve PSI-95, a 95% reduction in the scores, was also lower in the 0.1% 8-MOP/NB-UVB group, although the differences were not statistically significant. We conclude that topical 8-MOP cream enhances the therapeutic effects of targeted NB-UVB phototherapy without significantly increasing the short-term adverse effects.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Asawanonda P
Division of Dermatology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. pravit@adsl.loxinfo.com
Amornpinyokeit N
No affiliation info available
Nimnuan C
No affiliation info available

MeSH

Administration, TopicalAdolescentAdultCombined Modality TherapyDose-Response Relationship, DrugFemaleHumansMaleMethoxsalenMiddle AgedPhotosensitizing AgentsPsoriasisSkinUltraviolet Therapy

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

18181973

Citation

Asawanonda, P, et al. "Topical 8-methoxypsoralen Enhances the Therapeutic Results of Targeted Narrowband Ultraviolet B Phototherapy for Plaque-type Psoriasis." Journal of the European Academy of Dermatology and Venereology : JEADV, vol. 22, no. 1, 2008, pp. 50-5.
Asawanonda P, Amornpinyokeit N, Nimnuan C. Topical 8-methoxypsoralen enhances the therapeutic results of targeted narrowband ultraviolet B phototherapy for plaque-type psoriasis. J Eur Acad Dermatol Venereol. 2008;22(1):50-5.
Asawanonda, P., Amornpinyokeit, N., & Nimnuan, C. (2008). Topical 8-methoxypsoralen enhances the therapeutic results of targeted narrowband ultraviolet B phototherapy for plaque-type psoriasis. Journal of the European Academy of Dermatology and Venereology : JEADV, 22(1), 50-5. https://doi.org/10.1111/j.1468-3083.2007.02328.x
Asawanonda P, Amornpinyokeit N, Nimnuan C. Topical 8-methoxypsoralen Enhances the Therapeutic Results of Targeted Narrowband Ultraviolet B Phototherapy for Plaque-type Psoriasis. J Eur Acad Dermatol Venereol. 2008;22(1):50-5. PubMed PMID: 18181973.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Topical 8-methoxypsoralen enhances the therapeutic results of targeted narrowband ultraviolet B phototherapy for plaque-type psoriasis. AU - Asawanonda,P, AU - Amornpinyokeit,N, AU - Nimnuan,C, PY - 2008/1/10/pubmed PY - 2008/3/28/medline PY - 2008/1/10/entrez SP - 50 EP - 5 JF - Journal of the European Academy of Dermatology and Venereology : JEADV JO - J Eur Acad Dermatol Venereol VL - 22 IS - 1 N2 - Targeted broadband ultraviolet B (UVB) phototherapy as well as 308-nm excimer laser have been reported to significantly improve or clear localized psoriatic plaques within 5 to 10 treatments when medium fluences [i.e. 4-6 multiples of minimal erythema doses (MED)] were used. Our study was conducted to determine the effects of different concentrations of topical 8-methoxypsoralen (8-MOP) cream when used in combination with targeted UV phototherapy with regard to number of treatments and cumulative UV doses to clear localized psoriasis. Ten evaluable patients with stable plaque-type psoriasis completed the study. Three different concentrations of 8-MOP creams (0.001%, 0.01% and 0.1%) were applied prior to irradiation with 4 MEDs of targeted narrowband UVB (NB-UVB), whereas 0.001% 8-MOP cream was used in conjunction with 5 J/cm(2) UVA. All irradiations took place once weekly for 12 weeks. Psoriasis severity index (PSI) score was used to evaluate the efficacy of the treatment. With area-under-the-curve analysis, 0.1% 8-MOP/NB-UVB was superior to other modalities in reducing the PSI scores. The number of treatments and cumulative NB-UVB doses necessary to achieve PSI-95, a 95% reduction in the scores, was also lower in the 0.1% 8-MOP/NB-UVB group, although the differences were not statistically significant. We conclude that topical 8-MOP cream enhances the therapeutic effects of targeted NB-UVB phototherapy without significantly increasing the short-term adverse effects. SN - 1468-3083 UR - https://www.unboundmedicine.com/medline/citation/18181973/Topical_8_methoxypsoralen_enhances_the_therapeutic_results_of_targeted_narrowband_ultraviolet_B_phototherapy_for_plaque_type_psoriasis_ DB - PRIME DP - Unbound Medicine ER -